Oruka Therapeutics Management
Management criteria checks 1/4
Oruka Therapeutics' CEO is Lawrence Klein, appointed in Feb 2024, has a tenure of 1.25 years. total yearly compensation is $520.91K, comprised of 39% salary and 61% bonuses, including company stock and options. directly owns 2.28% of the company’s shares, worth €7.34M. The average tenure of the management team and the board of directors is 1 years and 1.3 years respectively.
Key information
Lawrence Klein
Chief executive officer
US$520.9k
Total compensation
| CEO salary percentage | 39.03% |
| CEO tenure | 1.3yrs |
| CEO ownership | 2.3% |
| Management average tenure | less than a year |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$521k | US$203k | -US$71m |
Compensation vs Market: Lawrence's total compensation ($USD520.91K) is below average for companies of similar size in the German market ($USD947.12K).
Compensation vs Earnings: Insufficient data to compare Lawrence's compensation with company performance.
CEO
Lawrence Klein (41 yo)
1.3yrs
Tenure
US$520,911
Compensation
Dr. Lawrence Otto Klein, Ph D, is Director of Jade Biosciences, Inc. Dr. Klein is Chief Executive Officer of Oruka Therapeutics and serves as its Director. Dr. Klein served as Partner of Versant Venture Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$520.91k | 2.28% € 7.3m | |
| General Counsel & Secretary | less than a year | US$310.45k | 0% € 0 | |
| Chief Medical Officer | less than a year | US$317.99k | 0.00051% € 1.6k | |
| Senior VP of Finance & Treasurer | 1.2yrs | no data | 0% € 0 | |
| Senior Vice President of Operations & Boston Site Head | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Vice President of Corporate Development & Strategy | no data | no data | no data | |
| VP and Head of Chemistry | no data | no data | no data | |
| Senior Vice President of Nonclinical Research & Development | no data | no data | no data |
1.0yrs
Average Tenure
49yo
Average Age
Experienced Management: HQ1's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$520.91k | 2.28% € 7.3m | |
| Independent Director | 1yr | US$20.55k | no data | |
| Independent Chairman of Board | 1.3yrs | US$27.74k | 0% € 0 | |
| Independent Director | 1.3yrs | US$20.38k | 0.23% € 734.2k | |
| Independent Director | 1.3yrs | US$19.18k | no data | |
| Independent Director | 1.3yrs | US$16.27k | 0% € 0 | |
| Chairman of Scientific Advisory Board | no data | no data | no data |
1.3yrs
Average Tenure
40yo
Average Age
Experienced Board: HQ1's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 00:32 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oruka Therapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |
| David Risinger | Leerink Partners LLC |